A $1 billion investment into future vaccines.

NEW VACCINE FACILITY OPENS

Australia’s onshore vaccine manufacturing capabilities “took a major leap forward” this week, as Minister for Health Mark Butler announces the opening of a new “state-of-the-art cell-based influenza vaccine and antivenom manufacturing facility in Melbourne”.

The Australian-owned and operated facility will use “innovative technology to manufacture seasonal and pandemic flu vaccines for Australia and the world”.

It will be is the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere and makes Australia one of only three countries with “end-to-end capability to make advanced cell-based influenza vaccines”.

“Thanks to this world-class facility, the future of flu vaccine and antivenom manufacturing is Australian made. World-leading flu vaccines that are in high-demand will be manufactured on our shores, to protect Australians and the globe.”

It will be operated by Australian giant CSL, with the new facility set to replace the existing CSL Seqirus egg-based vaccine manufacturing facility in Parkville, Melbourne – marking the end of an era after 80 years in manufacturing. 

CSL invested over $1 billion to build the “digitally enabled and environmentally sustainable facility”, with the Victorian government also contributing to the project.

They say this will “…reinforce the state’s already globally significant medical research and biotechnology community”.

The facility supports a long-term partnership with the Australian government to ‘protect Australia’s health’ by providing sovereign manufacturing capability and supply of pandemic influenza vaccines, antivenoms and Q fever vaccine. 

“In the event of an influenza pandemic, the facility and associated network have the capability to rapidly produce over 150 million vaccines in the first wave of manufacturing to help protect Australia and other nations.”

You certainly cannot deny that Melbourne has become the leader for vaccine manufacturing in Australia – not necessarily a title I would be proud of having.

Last year, after two years of construction, Moderna’s ‘world-class’ mRNA manufacturing facility opened in Victoria – with hopes to produce up to 100 million doses per year.

Australia’s first mRNA manufacturing facility officially opens
RELATED ARTICLE

Pfizer also announced a major upgrade to its manufacturing facility in Melbourne, now making it “one of Australia’s most advanced pharmaceutical production hubs”.

Pfizer upgrades Melbourne facility with $150 million investment
RELATED ARTICLE

Queensland is not far behind, with our government – alongside two Australian universities – also announcing they will collectively commit $280 million towards establishing a new mRNA ‘Translational Science Hub’ shortly after the ‘pandemic’.

QLD joins ‘mRNA revolution’ with plans for new research hub
RELATED ARTICLE

The ‘powers that be’ are dedicating resources to future ‘diseases’ and ‘pandemics’, with international ‘experts’ agreeing the next one is a matter of when, not if.

All of the signs point to yet another ‘pandemic’ or viral ‘disease’ lurking on the horizon – no doubt planned in advance just like Event 201 before COVID-19.

But if, or when it does happen, will the people fall for the ‘solution’ this time?

If current vaccination rates are anything to go by, it may be a different story than last time.

THE GREAT VACCINE TURN

Australians may not be as willing to lock themselves down, or roll up their sleeves for vaccinations, if a new ‘pandemic’ was to emerge once again.

The aftermath of such a world-shaking period has made people more distrusting of media than ever before – as rates continue to plummet across the county each year.

The Australian Medical Association, just a few days ago, called for “immediate action to combat vaccine hesitancy and reverse declining immunisation rates across the country”.

“We are seeing increasing global conversations about vaccine hesitancy, and it is putting lives at risk. Unfortunately, Australia is not immune, and it is deeply concerning to see declining rates here, especially among children,” said the press release.

This decline, particularly in the United States, has hit CSL’s revenue stream significantly – with a recorded 9 per cent decrease over the past year for vaccine departments.

Drop in immunisation rate hits Australian vaccine-maker’s revenue
RELATED ARTICLE

Can you blame the public for this scepticism?

Not just because of how they were treated over COVID-19, but also because of the shady history associated with the manufacturer themselves, CSL.

CSL Seqirus and the Australian government have partnered to deliver onshore manufactured vaccines for every ‘pandemic’ since 1919, and nearly 100 years of ‘lifesaving antivenoms’.

They have been marred in controversy for about as long.

For instance, the first Salk polio vaccines were distributed across Australia in June 1956, and 25 million doses were produced by CSL under Dr. Percival Bazeley’s directorship.

During this time, a federal government agency knowingly released polio vaccine contaminated with the monkey virus to the Australian public.

The virus contaminated at least four batches of vaccine totalling almost three million doses in Australia between 1956 and 1962.

An investigation revealed documents from the CSL found executives released one batch of about 700,000 doses of contaminated vaccine in 1962 with the understanding that “vaccines issued in the past were probably similarly contaminated“.

Learning From History: Infected Polio Vaccine
RELATED FEATURE

Interestingly, at the time, only 83 per cent of New South Wales children were vaccinated, as well only 72 per cent of children in Victoria. Authorities say due to the lack of ‘herd immunity’, this caused a second outbreak in 1961.

The same old story on repeat across the ages.

CSL is also being impacted by Donald Trump’s new pharmaceutical tariffs, which have wiped $1 billion in market value from the organisation – just as we warned was coming.

Australian Big Pharma companies may soon be hit by Trump tariffs
RELATED ARTICLE

So, it makes sense that CSL would be ecstatic with the new opening of this facility.

This allows them to ‘get back on the horse’ and attempt to re-correct their trajectory after all of these setbacks, but I doubt the people will be swarming for their new jabs any time soon.

$1 billion is quite the investment – one that all parties are looking for returns on.

Watch this space, and facility. ‘Big things’ may soon be coming.

KEEP UP-TO-DATE

For more TOTT News:

Facebook — Facebook.com/TOTTNews

YouTube — YouTube.com/TOTTNews

Instagram — Instagram.com/TOTTNews

Twitter — Twitter.com/EthanTOTT

Bitchute — Bitchute.com/TOTTNews

Gab — Gab.com/TOTTNews